OCGNOcugen, Inc.
Price
-47%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, the market against it.
Charts
As reported to the SEC, without any scoring.
Ocugen, Inc. (OCGN) reported revenue of $1.5M in Q2 2026 (quarter ended Jun 30, 2026), up 8.4% from the same quarter a year earlier. That came with net loss of $25M. For the full year FY2025, revenue was $4.4M (+8.8% year on year) and net income −$68M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 8, 2026On September 1, 2026, the Company announced that the first patient was dosed in the global Phase 3 registrational trial of OCU410 (AAV5-hRORA), its first-in-class modifier gene therapy candidate for Geographic Atrophy (“GA”) secondary to dry age-related macular degeneration (“dAMD”)Regulation FD disclosure · Form 8-K
- Aug 6, 2026Ocugen Provides Business Update with Second.Earnings release · press release
- Jul 13, 2026On July 13, 2026, Ocugen, Inc. (the “Company”) issued a press release announcing that it signed a binding term sheet for the license of OCU400 modifier gene therapy for retinitis pigmentosa in the Middle East and North Africa.Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.